



# ANAEMIA NEUTROPENIA THROMBOSIS AND CANCER COURSE

*Invitation to:*

**17<sup>th</sup> Annual Course  
Vienna, Austria  
March 16<sup>th</sup> - 17<sup>th</sup>, 2018**

**Chairs:**

M. Dicato, C. Bokemeyer,  
P. Gascon, H. Ludwig

**Course co-ordinator:**

M. Aapro

EACCME accreditation has granted 7 European CME credits (ECMEC®s).

The course has been approved to be announced as an ESO Recommended Event.

Endorsed by MASCC (Multinational Association of Supportive Care in Cancer)

AFSOS (French Speaking Supportive Care in Cancer Association)  
auspices have been requested.

A course made possible thanks to the support of the Genolier Cancer Center

## Friday, March 16<sup>th</sup>, 2018

- 10:00 Registrations Open
- 12:00-13:00 Buffet Lunch
- 13:00-13:10 Welcome: Chairmen and Coordinator
- 13.10-16:30 **SESSION 1: Anaemia in Cancer Patients**  
Chairman: *D. Schrijvers*
- 13:10-13:25 Pathophysiology, incidence and implications of anaemia in cancer patients  
*D. Schrijvers*
- 13:30-13:50 Transfusions: not a long-term alternative - *A. Hofmann*
- 13:55-14:20 Iron: a key component of anemia treatment - *Y. Beguin*
- 14:25-14:45 Break
- 14:50-15:10 Safety of EPOs in chemotherapy treated cancer patients: thrombosis and survival - *P. Gascon*
- 15:15-15:35 The 2017 ESMO Anaemia Guideline - *M. Apro*
- 15:40-15:55 Integrating iron management as per the ESMO guideline - *Y. Beguin*
- 16:00-16:25 Panel discussion: addressing the treatment options with questions from the audience chaired by D. Schrijvers
- 16:30-17:30 **SESSION 2: Biosimilars**  
Chairman: *M. Apro*
- 16:30-16:45 Lessons learned from observational studies with G-CSF: *M. Apro*
- 16:50-17:05 Clinical considerations for the development of biosimilars in oncology  
*M. Dicato*
- 17:10-17:25 Beyond EPO and G-CSF biosimilars: discussion with the audience: chaired by *M. Dicato*
- 17:30-18:30 **SESSION 3: Platelets or Thrombosis**  
Chairman: *M. Dicato*
- 17:30-17:50 New developments for thrombocytopenia management, ITP included - *C. Ay*
- 17:55-18:15 Thromboprophylaxis, and treatment of DVT and PE in ambulatory cancer patients - *A. Falanga*

# PROGRAM

## Saturday, March 17<sup>th</sup>, 2018

- 09:00-10:00 **SESSION 4: Neutropenia in Cancer Patients: a session in collaboration with MASCC (requested)**  
Chairman: *C. Bokemeyer*
- 09:00-09:15 Managing CDK4-6 induced neutropenia - *M. Aapro*
- 09:20-09:35 Development of new ESMO guidelines on neutropenia management - *M. Aapro*
- 09:40-09:55 Is there a case for long-acting G-CSF? - *H. Link*
- 10:00-10:20 ESMO position paper on Supportive and Palliative Care, ESMO guidelines in the area: *K. Jordan*
- 10:30-11:00 Break
- 11:00-11:50 **SESSION 5: The elderly cancer patient: a session in collaboration with AFSOS (requested)**  
Chairman: *M. Dicato*
- 11:00-11:20 Implications of anemia and neutropenia in the elderly patient - *D. Kamioner*
- 11:25-11:45 EPO and thrombopoietic agents in MDS - *V. Santini*
- 11:50-12:20 **SESSION 6: Beyond solid tumours**  
Chairman: *H. Ludwig*
- 11:50-12:15 Role of EPOs and G-CSF in lymphoma (Hodgkin's and non-Hodgkin's)  
*R. Pettengell*
- 12:20-12:35 **LEARNING ASSESSMENT (LA) FOR CME**
- 12:40... CME certificates given only to those participants who have completed the LA
- 13:00-14:00 Buffet Lunch